1- The CULPRIT-SHOCK Study Is Finally Published in NEJM and It Is Bound to Change Guidelines During SOLACI’s coverage of the TCT 2017 Congress in Denver, Colorado, we already mentioned some of the outcomes of this study that has arrived to revolutionize clinical practice, given the differences between its results and those of the classic<a href="https://solaci.org/en/2019/01/11/these-were-the-most-relevant-article-of-2018-in-the-field-of-coronary-diseases/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Transcatheter aortic valve replacement (TAVR) has emerged as a successful alternative for inoperable patients and a non-inferior alternative for high- and intermediate-risk patients. While its evolution depending on site experience has been analyzed, there is currently very little information regarding the impact of operator individual experience. This study analyzed 8771 procedures performed<a href="https://solaci.org/en/2019/01/09/is-individual-operator-experience-important-in-tavr/" title="Read more" >...</a>
In this pilot study, unloading the left ventricle with the Impella CP circulatory support device and delaying angioplasty by about 30 minutes appeared to be feasible and safe in patients with acute myocardial infarction without cardiogenic shock. This work sought to test the hypothesis that the device reduces ischemia-reperfusion injury. The trial included 50 patients who had the<a href="https://solaci.org/en/2018/11/30/aha-2018-more-evidence-for-the-impella-device-but-larger-trials-are-necessary/" title="Read more" >...</a>
Following up on the 30 day and one year effect, the IABP-SHOCK II trial long term outcomes showed there is not benefit to the use of intraaortic balloon counterpulsation in cardiogenic shock patients undergoing acute myocardial infarction. The only work in this group of patients with long term follow up is the SHOCK trial published in<a href="https://solaci.org/en/2018/11/27/aha-2018-use-of-balloon-counterpulsation-according-to-iabp-shock-ii-trial/" title="Read more" >...</a>
Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction or coronary angioplasty is quite frequent. According to this study (recently published in JACC), in a real-world population, the combination of direct anticoagulant agents and dual antiplatelet therapy reduces significantly the risk of bleeding and provides similar thromboembolic<a href="https://solaci.org/en/2018/11/20/safety-of-combining-new-anticoagulant-agents-and-dual-antiplatelet-therapy/" title="Read more" >...</a>
The last regional sessions for this year are coming full throttle! Within the framework of the 2018 Uruguayan Congress of Cardiology, SOLACI authorities alongside Uruguayan Society of Cardiology (SUC) authorities designed a broad scientific program, which includes the most up-to-date Latin American and international interventional cardiology topics and issues. Challenges in ischemic heart disease,<a href="https://solaci.org/en/2018/11/01/discover-the-scientific-program-for-the-2018-uruguay-sessions/" title="Read more" >...</a>
Time to endovascular treatment after ischemic stroke is strongly associated to functional outcomes. This association could be even stronger than previously suggested in more select populations of controlled studies. These findings emphasize that functional outcomes after endovascular treatment could be improved significantly by reducing onset to treatment times. Randomized studies in select acute<a href="https://solaci.org/en/2018/10/23/mr-clean-registry-time-is-brain-is-a-far-more-accurate-than-time-is-heart/" title="Read more" >...</a>
This study was aimed at gaining device registration from the US Food and Drug Administration (FDA) for a polymer-free biolimus A9 drug-coated stent (BioFreedom, Biosensors). The study had two purposes: on the one hand, it meant to reproduce the results of the LEADERS FREE trial (published in 2015) in terms of safety and efficacy with<a href="https://solaci.org/en/2018/10/03/tct-2018-leaders-free-ii-polymer-free-des-in-patients-at-high-risk-for-bleeding-with-1-month-of-antiplatelet-therapy/" title="Read more" >...</a>
Neoatherosclerosis was frequently observed in patients who experienced very late stent thrombosis, particularly those with drug-eluting stents. In-stent plaque rupture was the most common cause of thrombosis and it usually occurred in cases in which the original procedure had been carried out while the patient was undergoing an acute myocardial infarction. Macrophage infiltration can be<a href="https://solaci.org/en/2018/09/10/oct-provides-hints-about-the-physiopathology-behind-very-late-stent-thrombosis/" title="Read more" >...</a>
Defining dual antiplatelet therapy (DAPT) seems a never-ending story. We go from trials showing the safety of shorter schemes thanks to new generation stents to others suggesting up to two years of DAPT. Rather than finding a general scheme, it seems to be about adjusting DAPT on a case by case basis, according to ischemia<a href="https://solaci.org/en/2018/09/06/antiaggregation-time-after-treating-bifurcations/" title="Read more" >...</a>